Wavegate

Executive Summary

Wavegate is a San Diego-based private company developing the Ellipse spinal cord stimulator (SCS) platform, which integrates StimuLux optical reflectometry for closed-loop chronic pain management. Unlike conventional SCS systems, StimuLux enables real-time motion-responsive dosing, allowing dynamic adjustment of stimulation parameters based on patient movement. This technology supports both paresthesia-based and paresthesia-free paradigms, potentially improving patient comfort and outcomes while reducing side effects. The platform addresses a significant unmet need in the $6+ billion global SCS market, where current open-loop systems often lead to suboptimal pain relief or energy inefficiency. Wavegate's plug-and-play design aims to simplify clinician workflows and enhance patient adherence. The company has not disclosed funding or valuation, suggesting a relatively early development stage. However, its differentiated closed-loop approach with optical sensing positions it as a potential leader in next-generation neuromodulation. Key upcoming milestones include regulatory submissions and clinical data readouts that could validate the platform's superiority over existing therapies. Given the competitive landscape with established players like Medtronic and Boston Scientific, Wavegate's success hinges on demonstrating clear clinical and economic advantages.

Upcoming Catalysts (preview)

• Q3 2026FDA Submission for Ellipse SCS System70% success
• Q4 2026Publication of Pivotal Clinical Trial Results60% success
• TBDStrategic Partnership or Licensing Deal50% success